Granza Bio
PrivateLast Round
Seed
Jul 10, 2024
Total Funding Raised
$7.14M
Company Overview
Granza Bio is a biotechnology company that develops a cancer therapeutics platform aimed at assisting doctors in treating autoimmune diseases by specifically targeting cancer cells to minimize toxicity and side effects.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Granza Bio Comparables
Compare Granza Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Evox Therapeutics | 75% | |
| Entelexo Biotherapeutics | 69% | |
| FinalDose | 68% | |
Granza Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jul 10, 2024 |
Granza Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Refactor Capital | Seed |
| Pioneer Fund | Seed |
| Ritual Capital | Seed |
| Metaplanet Holdings | Seed |
| Ritual Capital | Seed |
| Zeno Ventures | Seed |
| Y Combinator | Seed |
Granza Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Granza Bio's valuation, stock price, and market status.